Maintained Survival Benefit With Trifluridine, Tipiracil in Refractory mCRC

Share this content:
The overall survival benefit associated with trifluridine/tipiracil (TAS-102) was maintained and increased to a full 2 months.
The overall survival benefit associated with trifluridine/tipiracil (TAS-102) was maintained and increased to a full 2 months.

The overall survival benefit associated with trifluridine/tipiracil (TAS-102) was maintained and increased to a full 2 months in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to an update survival analysis presented at the 2016 Gastrointestinal Cancers Symposium in San Francisco, CA.1

For the phase 3 RECOURSE trial, researchers randomly assigned 800 patients in a 2:1 fashion to receive trifluridine/tipiracil or placebo plus best supportive care.

At the time of the original analysis, median overall survival was 7.1 months (95% CI, 6.5 - 7.8) with the experimental agent vs 5.3 months (95% CI, 4.6 - 6.0) with placebo (HR, 0.68; 95% CI, 0.58 - 0.81; P < .0001). The 1-year survival rate was 26.6% (95% CI, 22.2 - 31.1) and 17.6% (95% CI, 12.7 - 23.1), respectively.

In this updated analysis, median overall survival was 7.2 months (95% CI, 6.6 - 7.8) for the trifluridine/tipiracil group compared with 5.2 months (95% CI, 4.6 - 5.9) for the placebo group (HR, 0.69; 95% CI, 0.59 - 0.81; P < .0001). The 1-year survival rate was 27.1% (95% CI, 23.3 - 30.9) with trifluridine/tipiracil and 16.6% (95% CI, 12.4 - 21.4) with placebo.

Of note, researchers found that the overall survival benefit appeared to be maintained for all patients regardless of baseline prognostic status.

RELATED: Screening Program May Help to Maximize Colorectal Cancer Screening Rates

Trifluridine is an antineoplastic thmyidine-based nucleoside analog and tipiracil is a thymidine phosphorylase inhibitor. The oral combination agent was approved by the U.S. Food and Drug Administration in September 2015 for the treatment of patients with mCRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and if RAS wild-type, an anti-epidermal growth factor receptor therapy.

Reference

  1. Mayer RJ, Ohtsu A, Yoshino T, et al. TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial [abstract]. J Clin Oncol. 2016;34(suppl 4S; abstr 634).

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs